The EU Commission approves subject to remedies a merger in the healthcare sector addressing the issues of potential competition and unilateral effects in innovative markets (Johnson & Johnson / Guidant)

"Johnson & Johnson/Guidant: potential competition and unilateral effects in innovative markets"*1. Introduction Following an in-depth investigation, on 25 August 2005 the European Commission authorised under the Merger Regulation the planned $ 24 billion (around € 18 billion) acquisition by US healthcare group Johnson & Johnson (J&J) of its competitor Guidant, a US company specialised in cardiovascular medical products, subject to a number of conditions designed to address the competition concerns identified in the course of the investigation. Both J&J and Guidant are active worldwide in the development, production and sale of vascular medical devices. Their products are used by physicians in procedures to treat vascular diseases both in the heart (coronary arteries)

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Alberto Bacchiega, Stéphane Dionnet, Mario Todino, Chloé MacEwen, The EU Commission approves subject to remedies a merger in the healthcare sector addressing the issues of potential competition and unilateral effects in innovative markets (Johnson & Johnson / Guidant), 25 August 2005, e-Competitions August 2005, Art. N° 37299

Visites 576

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues